|
🐜
|
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
27 auth.
N. Ruperto,
H. Brunner,
A. Ramanan,
G. Horneff,
R. Cuttica,
M. Henrickson,
J. Antón,
A. Boteanu,
I. Penadés,
K. Minden,
H. Schmeling,
M. Hufnagel,
J. Weiss,
M. Pardeo,
K. Nanda,
...
J. Roth,
N. Rubio-Pérez,
J. Hsu,
S. Wimalasundera,
C. Wells,
K. Bharucha,
W. Douglass,
M. Bao,
Navita L. Mallalieu,
A. Martini,
D. Lovell,
F. Benedetti
|
4 |
2021 |
4
🐜
|
|
🐜
|
Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial
22 auth.
H. Brunner,
N. Ruperto,
Z. Żuber,
R. Cuttica,
V. Keltsev,
R. Xavier,
R. Burgos-Vargas,
I. Calvo Penadés,
E. Silverman,
G. Espada,
...
Manuel Ferrandiz Zavaler,
Y. Kimura,
C. Duarte,
C. Job-Deslandre,
R. Joos,
W. Douglass,
S. Wimalasundera,
K. Bharucha,
C. Wells,
D. Lovell,
A. Martini,
F. De Benedetti
|
4 |
2020 |
4
🐜
|
|
🐜
|
Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial
15 auth.
Navita L. Mallalieu,
S. Wimalasundera,
J. Hsu,
W. Douglass,
C. Wells,
I. Penadés,
R. Cuttica,
H. Huppertz,
R. Joos,
Y. Kimura,
...
D. Milojevic,
M. Rosenkranz,
K. Schikler,
T. Constantin,
C. Wouters
|
4 |
2019 |
4
🐜
|
|
🐜
|
Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector
7 auth.
S. Fettner,
C. Mela,
Florian Wildenhahn,
M. Tavanti,
C. Wells,
W. Douglass,
...
Navita L. Mallalieu
|
3 |
2019 |
3
🐜
|
|
🐜
|
Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
15 auth.
C. Malattia,
N. Ruperto,
S. Pederzoli,
E. Palmisani,
A. Pistorio,
C. Wouters,
P. Doležalová,
B. Flatø,
S. Garay,
G. Giancane,
...
C. Wells,
W. Douglass,
H. Brunner,
F. De Benedetti,
A. Ravelli
|
3 |
2020 |
3
🐜
|
|
🐜
|
Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial
18 auth.
K. Bharucha,
H. Brunner,
I. Calvo Penadés,
I. Nikishina,
N. Rubio-Pérez,
S. Oliveira,
K. Kobusińska,
H. Schmeling,
F. Sztajnbok,
F. Weller-Heinemann,
...
E. Zholobova,
F. Zulian,
R. Allen,
J. Chaitow,
J. Frane,
C. Wells,
N. Ruperto,
F. De Benedetti
|
3 |
2018 |
3
🐜
|
